This retrospective analysis indicates that patients with advanced ALK- or ROS1-positive NSCLC who have been previously treated with ALK-TKIs can be treated in later lines with lorlatinib for prolonged periods of time. This evidence concerns the gene ALK and non-small cell lung carcinoma.